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Abstract Anti-cholinergic agents are considered the bronchodilator therapy of ¢rst-choice in the treatment of pa-
tients with stable chronic obstructive pulmonary disease (COPD) associated with heart disease since they may be as
e¡ective ormore e¡ective than inhaled b2-agonists and, moreover, theydo not interact with cardiac b-adrenoceptors.
The aim of our study was to evaluate the bronchodilator activity of oxitropium bromide in outpatients su¡ering from
exacerbations of COPD associated with heart diseases (ischaemic heart disease and/or arrhythmias).We recruited 50
consecutive outpatients (33 males and17 females, mean age 686 years,15 current smokers and 35 ex-smokers). Each
patient performed body plethismography in basal condition and 30min after inhalation of 200 mgmetered dose inhaler
(MDI) oxitropium bromide administered by a device (Fluspacers). FEV1, FVC,MMEF25-75, sRaw and tRaw were evalu-
ated.Thirty minutes after 200 mg oxitropium bromide administration, we observed a signi¢cant improvement in FEV1
116%71 (mean7SEM) (Po001);FVC,MMEF25-75 sRaw variationwasrespectively: 92%706,314729,199711. Pla-
cebo didnot signi¢cantlychangepulmonary function.Ourdata suggestthatoxitropiumbromidebronchodilator activity
is e¡ective in exacerbations of COPD.r2002 Elsevier Science Ltd
doi:10.1053/rmed.2001.1219, available online athttp://www.idealibrary.comon
Keywords acute exacerbation; COPD; oxitropium bromide.INTRODUCTION
The goals of treatment in acute exacerbation of chronic
obstructive pulmonary disease (COPD) are the prompt
resolution of symptoms andminimization of failure rate.
In most patients with acute exacerbations of COPD,
there appears to be a component of worsened air£ow
obstruction that is particularly responsive to bronchodi-
lators (1). Although the amount of reversibility achieved
mayberelatively small, any improvement in air£owcould
be extremely important in themanagement of these pa-
tients (1). For this reason, bronchodilators are recom-
mended in the management of this pathological
condition that is de¢ned as a worsening of COPD symp-Received 23April 2001and accepted in revised form25 September 2001.
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mcazzola@qubisoft.ittoms caused by a rapid deterioration of the underlying
respiratory function (2).
In particular, as the airwayobstructionbecomesmore
severe, the therapeutic option is to add a short-acting
inhaledb2-agonist, such as salbutamol, as rescuemedica-
tion to cause rapid relief of bronchospasm (3). Although
substantial incremental increase in forced expiratory
volume in 1 sec (FEV1) in response to increasing doses
of b-agonists beyond those commonly used in clinical
practice is restricted to a minority of patients (4), the
optimal dosage might be greater than the conventional
one (5).However, b-agonists have the potential to cause
some systemic side-e¡ects that aremore likely to occur
with higher doses (6).
Patients with COPD are of an age at which other
chronic diseases, including cardiac disease, are common.
Supraventricular and ventricular arrhythmias, as well as
conduction disturbances of varying severity are fre-
quently observed in COPD (7). The type of arrhythmia
TABLE 1. Demographic characteristics of the randomized
patients
Sex (M/F) 33/17
Age (years) 68(70?8)
Height (cm) 170(70?8)
Weight (kg) 70(71?3)
Smokinghistory (pack-years) 31(72)
Duration of disease (years) 9(71)
Values aremean (7SEM).
138 RESPIRATORYMEDICINEthat occurs in patients with COPD is in£uenced by their
clinical state. Co-existing coronary heart disease,
severe blood gas abnormalities and medication may
precipitate the rhythm disturbances (8). Many clinicians
are concerned about the potential e¡ect of bronchodila-
tors, particularly b2-agonists, on patients with cardiac
disease. Also, the chronotropic and electrophysiological
e¡ects of b2-agonists are enhanced by conditions of
hypoxaemia.
Since inhaled ipratropium is bene¢cial as immediate
therapy for asthma in the emergency department, some
practitioners attempted to extrapolate these ¢ndings to
treatment of COPD. In e¡ect, a few studies suggest the
e⁄cacy of ipratropium alone is comparable with that of
b2-agonists in acute COPD (9^12).
In the present study we have investigated the possible
acute e¡ects of a normal dose of oxitropium bromide,
which is another anti-cholinergic drug that has been
shown to produce a similar degree of bronchodilation to
thatobtainedwith ipratropiumbromide, butwith a long-
er-lasting e¡ect (13), in cardiopathic patients with acute
exacerbation of COPD.
METHODS
Fifty (33men and17women) consecutive outpatients pa-
tients su¡ering from acute exacerbation of COPD and
with a history of ischaemic heart disease or arrhythmias
supported by electrocardiogram (ECG) and/or Holter
ECG, or echocardiogramwere included in this study.
The diagnosis of COPD was consistent with the diag-
nostic standards of the consensus statementof European
Respiratory Society (ERS) (14) and established on the ba-
sis of clinical history, physical ¢ndings and spirometry. All
patients were 440 years of age, current or previous
smokers (410 pack-years) reporting chronic cough with
sputumproduction onmostdays during at least 3 conse-
cutive months in 2 consecutive years, had no change in
symptom severity or treatment in the preceding 4
weeks, had shown no signs of a respiratory tract infec-
tion in the month preceding or during the trial, were
not taking oral or inhaled corticosteroids for at least 3
months andhad a FEV1o65% and a forced vital capacity
(FVC)o 70% of predicted normal after bronchodilators
had been withheld for 24h and a best post-bronchodila-
tor FEV1/FVC of less than 07. Patients with a history of
asthma, allergic rhinitis, atopy, skin-test positivity or
with a totalblood eosinophil countover 400mm3 were
excluded. Acute exacerbationwas de¢ned as a sustained
worsening of the patient’s condition, from the stable
state and beyond normal day-to-day variations, that is
acute in onset and necessitates a change in regularmedi-
cation in a patient with underlying COPD (15). All pa-
tients presented increased sputum purulence and/or
volume, increased dyspnoea and/or wheeze, chest tight-ness and £uid retention, and had no indication for hospi-
talization, according to the BTS Guidelines (16). We
excluded patients with co-morbidities (such as conges-
tive heart failure or pulmonary embolus) or complica-
tions of COPD (e.g. pneumothorax) as the aetiology of
exacerbation of their symptoms. No patient was su¡er-
ing from febrile tracheobronchitis. Table 1 outlines the
baseline characteristics of the population studied.
No oral bronchodilators were permitted for 1 week
before andduring the study. Inhaled short-acting bronch-
odilator drugs and inhaled long-acting bronchodilator
agents were not permitted for at least 6 h and12h prior
to each test, respectively, but short-acting b2-agonists
were permitted soon after each test when required.
Consumption of cola drinks, co¡ee, tea and smoking in
the hours before and during the investigating were also
avoided. All patients received a treatment with an oral
antibiotic (co-amoxiclav or levo£oxacin) and an inhaled
steroid (budesonide 400mg or £uticasone 250mg twice
daily).
The study, which was conducted according to the
rules of the declaration of Helsinki andwas approved by
an independent scienti¢c ethics committee, was per-
formedusing a double-blind, cross-over, randomized de-
sign. All patients received two pu¡s of oxitropium
bromide (100mg pu¡1) or placebo which were inhaled
via matched MDI with spacer (Fluspacers), on two con-
secutive days.
Plethismographic testing was performed according to
the procedures described in the AmericanThoracic So-
ciety (17) before and 30min after inhalation of oxitro-
pium or placebo. Three acceptable forced expiratory
manoeuvres were performed in order to obtain two re-
producible results for FVC and FEV1. The highest FVC,
FEV1, maximal mid-expiratory £ow (MMEF2575), and
sRaw obtained from one or the other of the reproduci-
ble curves were kept for analysis. Between each plethis-
mographic test was a 3min pause, while patients
remained in sitting position. Contemporaneously, we
also measured oxygen saturation by pulse oximetry
(SpO2) and heart rate.
Symptoms (cough and dyspnoea) and vital signs (blood
pressure andheart rate) were assessed at the same time
intervals as the £ow rates. Just before each test, in basal
FIG. 1. FEV1value in basal condition and after inhalation of oxi-
tropiumbromide andplacebo.
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patients indicated the contemporary dyspnoea experi-
enced on a bipolar visual analogue scale (VAS).TheVAS
consisted of a 20 cm horizontal line labelled ‘very much
worse’ at the left end, ‘very much better’ at the right
end and ‘no change’ in themiddle.ThisVASmeasurement
has been shown to have an acceptable degree of within-
subject variability after inhalation of isotonic saline and
to correlate su⁄ciently with DFEV1 shortly after inhala-
tion of histamine or terbutaline (18). Every patient was
asked a subjective evaluation about cough.
All data analysiswas using a computer software and all
variables were reported asmean (7SEM) values.
The statistical analysis was performed using the SPSS
program (Statistical Package for the Social Sciences for
Windows, version 70, Chicago IL, U.S.A.). Analysis of
spirometric data for each treatment was performed
using the Student’s t-test for paired variables. Mean re-
sponses were also compared by multi-factorial analysis
of variance (ANOVA) to establish any signi¢cant overall
e¡ect between the two treatments. In the presence of a
signi¢cant overall ANOVA,Duncan’smultiple range test-
ing with 95% con¢dence limits was used to identify
where di¡erences were signi¢cant. A probability level of
Po005 was considered signi¢cant for all tests (19).
RESULTS
All patients completed the 2-day study. There were no
signi¢cant di¡erences (P4005) between the FEV1 va-
lues, blood pressure values, pulse rate, and SpO2 before
the two treatments (Table 2).
The improvements in FEV1 and FVC with oxitropium
bromide versus placebo were both signi¢cant (Po005).
Oxitropium bromide, but not placebo, induced a large
and signi¢cant (Po005) dose-dependent increase inTABLE 2. Mean (7SEM) values of functionalparameters attwo da
Oxitropium
Baseline 30min
FEV1(1) 1477008 1637
FEV1(%) 586725 6517
FVC(1) 233701 2537
FVC(%) 714732 8087
MMEF25-75(1) 0897007 1127
MMEF25-75(%) 296723 3827
sRaw 318703 2617
BP (mmHg) 145721 1507
85708 877
HR (bpm) 82717 857
SpO2(%) 9327031 9377
BP:Bloodpressure;HR: heart rate; SpO2: pulse oximetry.FEV1 (mean di¡erences from baseline: 160ml7113;
118%71; Fig.1).On the contrary, after inhalation of pla-
cebo, the mean per cent increase in FEV1was 25%702
(P4005). Analysis of the FVC,MMEF25-75, and sRaw re-
sponses showed e¡ects similar to that of FEV1. In parti-
cular, oxitropium induced an percentage increase in FVC
andMMEF25-75 of 92%706 (Po005) and 314%72?9%
(Po005), respectively, and a decrease in sRaw of 199%
711% (Po005) (Table 2).
Only 27 out of 50 patients reported dyspnoea at rest.
Twelve out of these 27 subjects, equal to 44% of them,
noti¢ed a mild improvement of this symptom after inha-
lation of oxitropium bromide [these subjects were ‘low
perceivers’ having a low level of perception of individual
dyspnoea (DVAS 5^35%, mean 20%)], whereas 10, equal
to 34%, reported a mild improvement after inhalation of
placebo. Patients accepted theVAS and thismade the as-
sessment of dyspnoea easier. There were no signi¢cant
modi¢cations of this symptom neither after the inhala-
tion of the anti-cholinergic agent nor after that of place-ysbaseline condition, afteroxitropiumor placebotreatment
Placebo
after Baseline 30min after
008 1457008 157008
27 578724 5947002
01 234701 235701
34 718731 736732
009 0897006 097007
27 296722 30724
02 319703 321703
18 146723 148714
06 83708 79707
2 83716 84717
033 9377032 9357033
140 RESPIRATORYMEDICINEbo, although there was a trend for a mild improvement
after oxitropium.
No signi¢cant changes in pulse rate, SpO2, bloodpres-
sure, or coughwere found after oxitropium as compared
with placebo group (Table 2).
No patient complained of adverse symptoms and did
not notice any di¡erence in the taste of the inhaler.
DISCUSSION
Exacerbations of COPD may cause speci¢c signs and
symptoms, such as increased dyspnoea, productive
cough with altered sputum and fever. Alternatively, the
symptomsmaybemore non-speci¢c, such asmalaise, fa-
tigue, insomnia or sleepiness and depression. Such ex-
acerbations are associated with impaired lung function
(15).
Unfortunately, it is oftenunknown at ¢rst approach to
the critically ill patientswith COPDhowmuch of the air-
wayobstructionmaybe reversiblewith bronchodilators.
Nonetheless, current guidelines (2, 14, 17) recommend
short-acting b2-agonists as ¢rst-line treatment of acute
exacerbation of COPD. There may be an advantage to
more frequent dosing, particularly in patients with initi-
ally severe bronchospasm, although at the expense of
more frequent side-e¡ects (20).
The use of b-agonists may be potentially arrhythmo-
genic in patients with acute exacerbation of COPD (21).
In fact, the chronotropic and electrophysiological e¡ects
of these agents are enhanced by conditions of hypoxae-
mia; mild hypoxaemia (SpO2r90%) has been demon-
strated to add something to prolongation of the QTc
caused by fenoterol (22).On the other hand, b-agonists
may decrease PaO2 by increasing blood £ow through
poorly ventilated areas of the lung (23), thereby increas-
ing ventilation/perfusion mismatch (24).When the initial
PaO2 is below 60mmHg, if a decrease in PaO2 is pro-
duced by a b2-agonist, it may become clinically signi¢-
cant. Consequently, b2-agonists therapy cannot be
consideredcompletely safe inpatientswith acute exacer-
bations of COPD. Furthermore, atrial and ventricular
dysrhythmias are frequent in this pathological condition,
occurring in as many as 80^90% of COPD patients with
respiratory failure (25). Hypoxaemia, right ventricular
enlargement associated left ventricular dysfunction, and
iatrogenic factors are potential determinants of the den-
sity and complexity of these arrhythmias (7). In particu-
lar, patients with hypoxaemic COPD may have a
subclinical autonomic neuropathy, which has been asso-
ciatedwith a prolonged electrocardiographQTc interval
and risk of ventricular arrhythmias and death (26).
Anti-cholinergics might, oppositely, be e¡ective
agents in the critically ill patients with COPD (27),
although the precise clinical role of anticholinergic com-
pounds in acute exacerbations of COPD is still unclear.Since inhaled anti-cholinergics are bene¢cial as immedi-
ate therapy for asthma in the emergency department,
somepractitioners attempted to extrapolate these ¢nd-
ings to treatment of COPD (28). Inhaled ipratropium is
commonly accepted as the drug of choice for long-term
management of chronic bronchitis and emphysema, but
little evidence is available to promote its administration
alone or in conjunctionwith a b2-agonist as part of initial
management of COPD exacerbations. Unfortunately,
studies that have compared ipratropium in combination
with b-agonists for acute exacerbations COPD have
found no particular addedbene¢t to the addition of ipra-
tropium to inhaledb-agonists (29^32).Perhaps therewas
no advantage in adding an anti-cholinergic agent because
the patients were already receiving maximum doses of
other bronchodilators (33). Anyway, anti-cholinergics
may have selective advantages for managing patients
who respond poorly to b2-agonist therapy alone (34).
Theresults of thepresent study suggest that anti-cho-
linergic agentsmay also have a role in ¢rst-line treatment
of acute exacerbation in COPD patients with pre-exist-
ing heart disease. Even though the reversibility tests
do not predict the degree of symptomatic bene¢t an
individual will obtain, we can presumed that the bronch-
odilatation with the reduction of airway resistance
may improve exercise tolerance and reduce respiratory
fatigue.
Our data have clearly demonstrated that oxitropium
not only induced a substantial bronchodilation, but was
also safe. In fact, it did not induce signi¢cant modi¢ca-
tions inheartrate or in SpO2, although four patients pre-
sented at baseline a decrease in SpO2 under 90%. This
¢nding is a true advantage of an anti-cholinergic agent,
which may be particularly important in the critically ill
patientwithmultiple organ failure inwhom excessive ta-
chycardia may reduce oxygen delivery (28).
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